Knight Therapeutics Inc. saw a notable decline in its stock price during yesterday's trading session, raising concerns among investors.
In yesterday's session, Knight Therapeutics Inc. (GUD.TO) experienced a drop of 2.21%, closing at CA$9.29. This decline comes despite the company reporting significant revenue growth in its recent earnings announcements, which may leave investors questioning the stock's performance amid positive fundamentals.
Advertisement
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeAdvertisement
Market cap
$933.20M
P/E
63.3x
52W high
$10.17
52W low
$5.66
1W change
+0.32%
Beta
0.05
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 16.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$10.83
+16.6% Upside
Current Price
C$9.29
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
29.5%
Annualized
90-Day Vol
31.7%
Annualized
Trend (90d)
+40.8%
Annualized drift
90d Mean
C$10.75
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.75 | C$8.81 – C$10.80 |
| 60 trading days | C$10.24 | C$8.87 – C$11.82 |
| 90 trading days | C$10.75 | C$9.01 – C$12.82 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should remain cautious as Knight Therapeutics faces market volatility, even with strong revenue growth reported in its latest earnings.
Stock Decline of 2.21%
Knight Therapeutics' market cap stands at approximately CA$933 million, reflecting investor sentiment amidst fluctuating stock performance.
Bull case
Knight Therapeutics has shown impressive revenue growth, with a reported 68-69% year-over-year increase in Q1 2026. This suggests a solid business model and potential for future profitability.
Bear case
The recent stock decline of 2.21% may indicate underlying market concerns or investor sentiment that could overshadow the company's positive financial results.
Advertisement
Market Reaction to Earnings
Despite Knight Therapeutics reporting record revenues of CA$148 million for Q1 2026, the stock fell yesterday. Investors may be reacting to broader market trends or specific concerns about the company's future performance.
Concerns Amid Growth
The decline in Knight Therapeutics' stock price, despite its impressive year-over-year revenue growth, highlights potential investor skepticism. The high P/E ratio of 61.93 suggests that the stock may be overvalued, leading to increased volatility.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
